8 April 2022 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Antibiotic-associated diarrhea (AAD) is a key aspect of pediatrics concerning antibiotic therapy Purpose. The article aims at investigating the effects of colloidal silicon dioxide in the treatment of antibiotic-associated diarrhea in children. Materials and methods. Using parametric and nonparametric methods of analysis, 83 patients were examined (treatment group — 41 children who used colloidal silicon dioxide and the control group — 42 children) of both sexes (mean age (13.7 ± 2.6) years) with pathology of the lower respiratory tract (acute bronchitis or community-acquired pneumonia), who developed AAD against the background of ABT. Results. When using colloidal silicon dioxide in 75.6% of children, diarrhea decreased by the 2nd day and stopped by the 4th day (median — 0 points). Against the background of taking the drug throughout the treatment, there was a marked 3-fold decrease in all AAD values. The assessment of the efficacy and safety of the drug according to the data of medical researchers was 3.4 points. Analysis of subjective data on the tolerability of the drug showed «excellent» and «good». Against the background of the full course of treatment with colloidal silicon dioxide, a 2 times more pronounced decrease in the characteristics of AAD was noted. Conclusion. The presented data are intended to focus the attention of pediatricians on the rational use of ABT, timely diagnosis of an unwanted drug reaction in the form of AAD and its correction. The studied drug showed high efficacy and safety, which makes it possible to recommend it as a symptomatic treatment of diarrhea that developed against the background of ABT treatment in the complex therapy of diseases of the lower respiratory tract in children.
28 November 2020 in Meditsinskiy sovet = Medical Council
Потенциал использования противокашлевой терапии в педиатрической практике
21 March 2021 in Meditsinskiy sovet = Medical Council
Introduction. Cough accompanies an acute infectious process in the respiratory tract. The article focuses on the symptomatic treatment of cough using a modern herbal preparation with complex action and standard therapy.Goal. To study the effects of a herbal preparation with complex action in the treatment of cough in children.Materials and methods. The study included 72 patients of both sexes (mean age 14.6 ± 2.3 years) with a symptom of unproductive/unproductive cough, against the background of acute bronchitis or community-acquired pneumonia.Results and discussion. When using a herbal preparation with complex action was used in ¾ of the children, cough decreased by the 3rd day and in most patients it stopped by the 10 th day. The severity of daytime and nighttime coughs decreased by 3.0–3.5 points, the number of seizures decreased to 2–4 per day, the duration of seizures also decreased significantly, the median of this indicator in the main group reached 0 points. In both groups, the proportion of patients with seizure frequency of no more than 4 per day increased. While taking a herbal preparation, a more pronounced decrease in all indicators of cough by 3.5 times was noted throughout the treatment, and the corresponding effects developed 3 days ahead of time against the background of a full course of therapy. The average value of the efficacy and safety assessment given by the medical researchers to the action of the herbal preparation with complex action was 3.6 points. Analysis of objective and subjective data based on the results of evaluating case histories and individually developed questionnaires for patients on drug tolerance showed equivalence in terms of excellent and good results. Against the background of the full course of treatment with the herbal preparation, a 1.8 times more pronounced decrease in the characteristics of the cough syndrome was noted.Conclusion. The drug has shown high efficacy and safety, which makes it possible to recommend it as a symptomatic therapy for cough in school-age children as part of a combination or monotherapy.
28 July 2023 in Meditsinskiy sovet = Medical Council
Introduction. Acute respiratory viral infections hold a dominant place in the infectious diseases pattern. There are many drugs that can affect separate arms of the immune response.Aim. To analyze the effectiveness of the systemic use of a combined drug containing interferon-α-2b and a complex immunoglobulin preparation in the treatment of respiratory diseases in frequently ill children.Material and methods. We examined 103 children aged 2-12 years. Upon admission, the children were treated with a combined drug containing interferon a-2b and a complex immunoglobulin preparation (CIP) (Kipferon®) rectally. Children in the control group received standard therapy.Results. Children were admitted to the hospital in the first days of the disease (66.02%), mainly in the moderate form of the disease (96.12%). 81.55% had symptoms of intoxication, catarrhal phenomena and respiratory syndrome. Comparing the time from the onset of the disease when prescribing IFN-α-2b to children, their significantly significant differences were established. Introduction in the early stages of the disease contributes to a faster elimination of all symptoms: fever stopped on average (M ± SD) after 1.76 ± 0.33 and 2.05 ± 0.29 days, respectively, from the moment of admission to the hospital, which was on average 2 days less than in the control group. The transition to a productive cough in the main group occurred on average (M ± SD) after 3.25 ± 0.27 days, in the comparative group - after 5.23 ± 0.31, in the control group - after 8.19 ± 0.42 days. In patients of the main and comparative groups, the length of stay in the hospital was significantly shorter - on average (M ± SD) 8.04 ± 0.81 days than in the control group - 10.56 ± 1.42 days. Hematological parameters returned to normal at an earlier time.Discussion. Rectal route of recombinant IFNi-a2b delivery as suppositories is substantiated with regard to etiopathogenesis and immunology.Conclusion. The article presents the outcomes of the clinical use of Kipferon® as part of the combination therapy and prevention of complications of acute respiratory viral infections in children: reduced duration of intoxication, fever, faster improvement of the auscultatory status of the lungs, improvement of immune status indicators.
27 July 2023 in Meditsinskiy sovet = Medical Council
The article focuses on the most frequent skin diseases in young children. Atopic/allergic dermatitis is one of the most common diseases in children. Approximately 45% of patients develop their first symptoms within the first 6 months after birth, 60% show the onset of atopic dermatitis during the first year of life and 80-85% at the age of 1 to 5 years. The article also speaks about the issue of allergic contact dermatitis (diaper rash in newborns). The disease represents non-specific inflammatory skin changes in the contact area in infants, the onset of which occurs mostly at the age of 1 to 15 months. The factors responsible for causing these diseases, the pathogenesis of their development and the potential of topical therapy mainly targeted at the reduction of clinical manifestations and frequency of exacerbations, improvement of the quality of life and prevention of infectious complications are considered. As an initial treatment, the authors consider a drug containing methylprednisolone aceponate with ceramides of domestic manufacturing. Its effectiveness and safety in the combination therapy of young children suffering from atopic/allergic and contact dermatitis may be evaluated in clinical practice. Clinical case reports of treatment of children with dermatitis of various etiologies aged from 4.5 months up to 3 years are presented. The outcomes of the use of Komfoderm K in children with AD demonstrated a significant decrease in the severity of inflammation, reduction of the skin lesion area and the intensity of symptoms, decreased need for additional intake of antihistamines and anti-inflammatory drugs, and the ability to achieve stable clinical remission.
8 April 2024 in Meditsinskiy sovet = Medical Council
Introduction. All acute respiratory infections are characterized by damage to the mucous membrane of the respiratory tract, a decrease in local immune defense and a weakening of nonspecific protective factors.Aim. To characterize the clinical effectiveness of the use of the immunocorrective drug in frequently ill children.Materials and methods. The article assessed the microbiological spectrum of the rhinopharyngeal landscape in 65 children: 33 children took an immunocorrective drug in addition to conventional therapy – the main group; 32 children received conventional therapy (the comparison group), and also investigated the possibility of regulating their polypathogenic microbiota using topical bacterial lysates.Results and discussion. The result of the therapy was a clinical improvement characterized by the relief of pharyngoscopic signs of chronic tonsillitis in children while taking topical bacterial lysates in form of lozenges. Analysis of the microbiota of the oropharyngeal mucosa in the studied patients of both groups before the start of therapy revealed the species diversity of opportunistic flora, among which Streptococcus pyogenes, Staphylococcus aureus, the family Enterobacteriaceae and Candida albicans were identified in all patients in diagnostic significant titers of 105–1010. After treatment in the main group, the ratio of the microbiota of the nasopharynx significantly changed, stimulation of the production of local immunity components was noted, which was confirmed by a decrease in the intensity of contamination of microbiota with polypathogenic functions to diagnostically insignificant titers. When comparing the species composition of the microbiota in the studied groups after treatment with topical bacterial lysates, a statistically significant positive effect was found without additional use of antibacterial drugs.Conclusions. It has been shown that the immunocorrective drug eliminates pharyngoscopic signs of rhinopharyngeal dysbiosis in children who are often and long-term ill.